Cited by 667Chronic Kidney Disease and DiabetesLipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities Study

Open access
Muntner, Paul, Coresh, Josef, Smith, J. Clinton, Eckfeldt, John, Klag, Michael J.·2000·Kidney International

Abstract

Background Animal and in vitro data suggest that dyslipidemia plays an important role in the initiation and progression of chronic renal disease, but few prospective studies have been conducted in humans. Methods We studied the relationship of plasma lipids to a rise in serum creatinine of 0.4 mg/dL or greater in 12,728 Atherosclerosis Risk in Communities (ARIC) participants with baseline serum creatinine that was less than 2.0 mg/dL in men and less than 1.8 mg/dL in women. Results During a mean follow-up of 2.9 years, 191 persons had a rise in creatinine of 0.4 mg/dL or greater, yielding an incidence rate of 5.1 per 1000 person years. Individuals with higher triglycerides and lower high-density lipoprotein (HDL) and HDL-2 cholesterol at baseline were at increased risk for a rise in creatinine after adjustment for race, gender, baseline age, diabetes, serum creatinine, systolic blood pressure, and antihypertensive medication use (all P trends </=0.02). The adjusted relative risk for the highest versus lowest quartile of triglycerides was 1.65 (95% CI, 1.1, 2.5, P = 0.01) and for HDL was 0.47 (95% CI, 0.3, 0.8, P = 0.003). These associations were significant in participants with normal creatinine (defined as <1.4 mg/dL for men and <1.2 mg/dL for women), with diabetes, and without diabetes. The effect of high triglycerides was independent of plasma glucose, but was weaker and less consistent after further adjustment for fasting insulin in nondiabetics. Conclusions High triglycerides and low HDL cholesterol, but not low-density lipoprotein cholesterol, predict an increased risk of renal dysfunction. The treatment of these lipid abnormalities may decrease the incidence of early renal disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1523-1755.2000.00165.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • HDL has been shown in animals and humans to be reno-protective.

    “but has been shown in animals and humans to be reno-protective [35]”

    From Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study (2011) · cites this paper as [35]

    The Results passage (page unavailable in our copy) associates higher HDL cholesterol with a lower risk of a rise in creatinine in humans, but this observational finding does not show that HDL itself protects the kidney. The paper’s discussion of animal models reports reduced renal injury after lipid-lowering treatment, not a protective effect specifically attributable to HDL. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • Dyslipidemia is a risk factor for progressive kidney disease.

    “While dyslipidemia is a risk factor for progressive kidney disease (8,10,20,21)”

    From Effects of Fibrates in Kidney Disease (2012) · cites this paper as [10]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cited by

Sorted by citations

Authors
Muntner, P., Coresh, J., Smith, J. C., Eckfeldt, J., & Klag, M. J.
Affiliations
  • University of Minnesota (US)
  • Johns Hopkins University (US)
Corresponding author
Coresh, Josef
Venue
Kidney International
Publisher
Elsevier BV
Published
2000-07
Volume
58
Issue
1
Pages
293-301
ISSN
0085-2538 (ISSN-L)
OpenAlex
W2012766272
Cited by
667
References
2
Citations by year
2026: 9 · 2025: 12 · 2024: 23 · 2023: 18 · 2022: 28 · 2021: 40 · 2020: 26 · 2019: 25 · 2018: 26 · 2017: 16 · 2016: 39 · 2015: 26 · 2014: 28 · 2013: 32 · 2012: 32
FWCI
10.68
Type
journal article
Language
en
Open access
Locations
  • Kidney International (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (n01hc55016-37-0-0, n01hc55019-35-0-1, n01hc55015-48-0-1)
  • National Heart, Lung, and Blood Institute (N01 HC 55019, ­N01-HC55016, N01‐HC‐55015)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
plasma lipids, renal dysfunction, chronic kidney disease, triglycerides, HDL cholesterol, HDL2, LDL cholesterol, serum creatinine, dyslipidemia, diabetes mellitus, fasting insulin, Atherosclerosis Risk in Communities Study
MeSH terms
Arteriosclerosis, Creatinine, Female, Follow-Up Studies, Humans, Kidney Failure, Chronic, Cholesterol, HDL, Male, Middle Aged, Prospective Studies, Risk Factors, Triglycerides, Incidence, Renal Insufficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review